.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,180,582

« Back to Dashboard

Claims for Patent: 4,180,582

Title: 6-n-Propyl-8-methoxy-methyl or methylmercaptomethylergolines and related compounds as prolactin inhibitors and to treat Parkinson's syndrome
Abstract:6-n-Propyl (ethyl or allyl)-8.beta.-methoxy-(methyl-sulfinyl, methylsulfonyl, or methylmercapto) methylergolines, 8-ergolenes or 9-ergolenes, useful as prolactin inhibitors and in the treatment of Parkinsonisn.
Inventor(s): Kornfeld; Edmund C. (Indianapolis, IN), Bach; Nicholas J. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:06/002,515
Patent Claims: 1. A process for inhibiting the secretion of prolactin in mammals which comprises administering to a mammal in which there is an excess of prolactin being secreted a prolactin-lowering dose of a compound of the formula ##STR3## wherein Y is O, SO, SO.sub.2 or S, R.sup.1 is ethyl, n-propyl, or allyl, X is H, Cl or Br and R.sup.2, R.sup.3 and R.sup.4 when taken singly are hydrogen, and R.sup.2 and R.sup.3, and R.sup.3 and R.sup.4, when taken together with the carbon atoms to which they are attached, form a double bond, and pharmaceutically-acceptable acid addition salts thereof.

2. A process for treating a patient suffering from Parkinson's syndrome and in need of treatment which comprises administering a dose effective to ameliorate the Parkinsonism symptoms of a compound of the formula ##STR4## wherein Y is O, SO, SO.sub.2 or S, R.sup.1 is ethyl, n-propyl, or allyl, X is H, Cl or Br and R.sup.2, R.sup.3 and R.sup.4 when taken singly are hydrogen, and R.sup.2 and R.sup.3, and R.sup.3 and R.sup.4, when taken together with the carbon atoms to which they are attached, form a double bond, and pharmaceutically-acceptable acid addition salts thereof.

3. A method according to claim 2 in which D-6-n-propyl-8.beta.-methylmercaptomethylergoline or a pharmaceutically acceptable salt thereof is administered.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc